43. Murshed M, Schinke T, McKee MD, Karsenty G (2004) Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165: 625–630. 44. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, et al. (2002) Tissue- nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 99: 9445–9449. 45. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, et al. (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102: 3324–3329. 46. Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, et al. (2008) Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456: 997–1000. 47. Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, et al. (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 3: 903–910. 48. Ge H, Cha JY, Gopal H, Harp C, Yu X, et al. (2005) Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 46: 1484–1490. 49. Kim KH, Cho YS, Park JM, Yoon SO, Kim KW, et al. (2007) Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Lett 581: 3303–3310. 50. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, et al. (2006) Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 20: 2432–2443. 51. Iwami K, Moriyama T (1993) Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int J Biochem 25: 1631–1635. 52. Schroeder TM, Westendorf JJ (2005) Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 20: 2254–2263. 53. Boer JD, Licht R, Bongers M, Klundert TV, Arends R, et al. (2006) Inhibition of Histone Acetylation as a Tool in Bone Tissue Engineering. Tissue Eng. Hdac3 Regulates Bone Density 54. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, et al. (2000) Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11: 2069–2083. 55. Pratap J, Dhillon R, Li X, Wixted J, Akech J, et al. (2008) The Histone Deacetylase Inhibitor, Vorinostat, Blocks Growth and Associated Osteolysis of Cancer Cells Within Bone, but Reduces Bone Volume in Non-Tumor Bearing Bones in Mice. Journal of Bone and Mineral Research 23 (Suppl 1). 56. Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351–1356. 57. Wiech NL, Fisher JF, Helquist P, Wiest O (2009) Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. Curr Top Med Chem 9: 257–271. 58. McGee-Lawrence ME, Wojda SJ, Barlow LN, Drummer TD, Bunnell K, et al. (2009) Six months of disuse during hibernation does not increase intracortical porosity or decrease cortical bone geometry, strength, or mineralization in black bear (Ursus americanus) femurs. J Biomech 42: 1378–1383. 59. Iwaniec UT, Wronski TJ, Turner RT (2008) Histological Analysis of Bone. In: Nagy LE, ed. Alcohol: Methods and Protocols: Humana Press. pp 325–341. 60. Gallay SH, Miura Y, Commisso CN, Fitzsimmons JS, O’Driscoll SW (1994) Relationship of donor site to chondrogenic potential of periosteum in vitro. J Orthop Res 12: 515–525. 61. Reinholz GG, Fitzsimmons JS, Casper ME, Ruesink TJ, Chung HW, et al. (2009) Rejuvenation of periosteal chondrogenesis using local growth factor injection. Osteoarthritis Cartilage 17: 723–734. 62. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034. 63. Pfaffl MW (2001) A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res 29: e45. PLoS ONE | www.plosone.org 15 July 2010 | Volume 5 | Issue 7 | e11492